


INTERIM RESULTS

For the period July 2021 to December 2021

Agenda



INTERIM RESULTS For period ended 31 December 2021



GG

Our business is focused on making a sustainable impact in the area we know best - healthcare. OUR BUSINESS

HEALTHIER TOGETHER

HER



BUSINESS CONTEXT & HIGHLIGHTS

Group CEO I Ahmed Banderker

COVID insights

4th Wave Insights

- The 4th wave has been significantly less severe
- 4th wave hospitalisations are around 50% lower than 3rd wave
- Total hospital costs estimated more than 80% lower than 3rd wave, with around 90% fewer deaths




- The State of Disaster should have been relaxed
- Allow vaccinated offices to return to full capacity
- Virtualisation of health
- Re-evaluate the rollout plans for NHI




Scheme Client Considerations

- Scheme surpluses generated in 2021 were on average 4.2% higher than budget
- Electives are increasing to precovid levels
- How do we make healthcare more affordable and accessible





4





Emerging health trends following Covid





Delivering value to our scheme clients

Annualised Health Risk Management Savings


R4.43 billion*

*Annualised

ENHANCING ACCESS TO CARE



Savings per member per month **R230**




*Estimation annualised using Jan - Sep 2021

INTERIM RESULTS For period ended 31 December 2021



2022 Interim business highlights

Solid financial performance despite challenging trading conditions







Business update

INTERIM PROGRESS UPDATE

Corporate Activity



- Merging of Nedgroup Medical Aid with Bonitas
- Retained 14 000 of NMAS
 members

New Business

Ζ.

- Famous Brands On-site clinics
- Coca-Cola beverages HIV Programme
- Samwumed managed care
- The GEMS vitamin supply

Retail

- 48% drop in anti-malaria sales volume
- 32% decrease in multivitamin sales
- Unfavourable EBIT due to reduction in adherence to chronic medication
- Pharmacy Direct delivered 1.4 million Activo multi-vitamins to high-risk patients

INTERIM RESULTS For period ended 31 December 2021



9



Business Solutions Offering





Sanlam's plan to launch new health insurance offerings with AfroCentric is perhaps the most exciting.

- Paul Hanratty - Sanlam CEO

"

INTERIM RESULTS For period ended 31 December 2021



10



Combined with diversified business model and client-centricity, we are positioned to drive superior long-term value





For period ended 31 December 2021






SEGMENTAL REVIEW & FINANCIAL HIGHLIGHTS

Group CFO I Hannes Boonzaaier

Segmented operating profit and Diversification drive



HEALTHIER TOGETHER

INTERIM RESULTS For period ended 31 December 2021



Normalised trading view excluding non-recurring items

Non-recurring events which occurred during the period to date:

Vaccination programme investment (R25m)

Impact of non adherence to chronic medication (R22m)

Normalised trading view

| | Normalised trading Including adjustment | As reported Excluding adjustment | Normalised trading Unaudited six months ended 31 December 2021 | As reported Unaudited six months ended 31 December 2021 | Trading adjustments |
|------------------------------------|--|-------------------------------------|---|--|------------------------|
| Operating profit | 13,7% | 4,6% | 582,1 | 535,1 | 47,0 |
| Profit after tax | 15,8% | 1,3% | 267,2 | 233,6 | 33,6 |
| Headline earnings (rands) | 19,3% | 3,4% | 178,4 | 154,4 | 24,0 |
| Normalised headline earnings (rand | s) 19,2% | 3,2% | 31,0 | 26,9 | 4,2 |






3 year view of profit before tax

R535.5m

Group EBITDA

(2020 - R511.8 m)


| Amortisation YOY Increase | Increase (R'm) | Increase (%) |
|--------------------------------------|-------------------|-----------------|
| Administration Systems | 17 | 37% |
| Activo Healthcare Assets Dossiers | 10 | 100% |
| Insurance Fraud Manager | -10 | -61% |





Scheme membership


- Overall, membership is under pressure due to affordability and profile of members.
- Steady growth from GEMS, but notable losses from various Closed Schemes.






Segmented financial reporting structure-services - Services

Medical Aid administration, Risk management & Technology: Concentrating on improving the operational delivery model of services






Scripts dispensed




Retail Cluster operating profit







Segmented financial reporting structure - Retail


Pharma: Performance supported by diverse customer base in private and public sector.












For period ended 31 December 2021




21


Cash conversion cycle



Additional Activo inventory:

HEALTHIER TOGETHER






| Dec 2021 | June 2021 |
|----------|-----------------------------|
| 80,3 | 95,1 |
| 41,7 | 37,6 |
| 27,9 | 29,7 |
| 10,7 | 27,8 |
| | 80,3 41,7 27,9 |

INTERIM RESULTS 22



Statement of financial position



FORRESTER ACQUISITION


The conclusion of the Forrester acquisition at a total purchase price of R300m of which R190m was settled. The transaction had the following impact of the statement of financial position:

- Goodwill R157m
- Intangible assets R180m
- Deferred payment liability R96m
- Borrowings R140m

INVESTMENT IN INSURANCE CONTRACT

Investment in the Sanlam Gap cover business, which is managed through a cell captive arrangement by Centriq Insurance Company Limited.

HEALTHIER TOGETHER



INTERIM RESULTS

For period ended 31 December 2021

23

AfroCentric

Group performance - investor dashboard

| Description | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | 5 year Compound annual growth rate |
|---------------------------------------|----------|----------|----------|----------|----------|---------------------------------------|
| Total Revenue (R'm) | 2 038 | 2 307 | 3 111 | 3 898 | 4 289 | 20,4% |
| Operating Profit (R'm)* | 284 | 295 | 398 | 469 | 496 | 15,0% |
| Group Operating Profit Margin (%) | 13,9% | 12,8% | 12,8% | 12,0% | 11,6% | -4,5% |
| Comprehensive Headline Earnings (R'm) | 177 | 175 | 206 | 233 | 232 | 7,0% |
| Normalised Headline Earnings (R'm) | 120 | 121 | 140 | 152 | 152 | 6,1% |
| Normalised HEPS (cents) | 21,67 | 21,78 | 24,36 | 26,48 | 26,51 | 5,2% |
| Membership (lives managed) | 3 625 | 3 711 | 3 829 | 3 880 | 3 788 | 1,1% |
| Scripts dispensed | 2 939 | 4 402 | 4 982 | 6 256 | 7 207 | 25,1% |
| Dividends (cents) | 16 | 17 | 17 | 17 | 17 | 1,5% |
| Share price (Rand) | 6,4 | 4,86 | 3,39 | 3,80 | 5,26 | |
| Annualised Dividend Yield (%) | 5,00% | 7,00% | 10,03% | 8,95% | 6,46% | |
| Annualised Return on Equity (%) | 13,7% | 13,1% | 13,2% | 14,1% | 14,1% | |
| NAV per share (Rand per share) | 4,56 | 4,87 | 5,23 | 5,54 | 5,81 | 6,3% |
| | | | | | | |

*Excluding IFRS 16 lease reversals

HEALTHIER TOGETHER For period ended 31 December 2021











